Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma By Ogkologos - July 2, 2025 260 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Gastric04 study Source RELATED ARTICLESMORE FROM AUTHOR Worse Survival Observed Among Patients Diagnosed with Cancer During the First 2 Years of the COVID-19 Pandemic AI-Supported Mammography Screening Shows Favourable Outcomes Compared with Standard Double Reading ESMO Welcomes European Parliament Resolution Marking World Cancer Day MOST POPULAR High Response Rates Observed Following KTE-X19 CAR T-Cell Therapy in Adults... June 15, 2021 Could proton beam therapy improve throat cancer treatment? March 15, 2021 Atezolizumab Approved for Some Patients with Triple-Negative Breast Cancer March 28, 2019 FDA Approvals Expand Initial Treatment Options for Multiple Myeloma January 7, 2025 Load more HOT NEWS News digest – cancer blood test, gum disease and junk food... Female Breast Cancer is Now the Most Commonly Diagnosed Cancer in... FOCUS4: Learning from a landmark clinical trial Two Years After Cancer Diagnosis, Swimmer Rikako Ikee Has Qualified For...
